TABLE 2.
Data for subgroup analysis assessing patients receiving SGLT‐2 inhibitors and GLP‐1 analogues
| SGLT‐2 Group | P | GLP‐1 Group | P | |||
|---|---|---|---|---|---|---|
| Baseline (n = 22) | 6 mo (n = 21) | Baseline (n = 17) | 6 mo (n = 15) | |||
| Sex (M/F) | 12/10 | 8/9 | ||||
| Age (y) | 56 (50‐62) | 66 (56‐68) | ||||
| Transient elastography | ||||||
| CAP (dB/m) | 338 (311‐371) | 336 (274‐353) | .014 | 341 (316‐360) | 337 (295‐368) | .562 |
| LSM (kPa) | 6.4 (5.3‐7.4) | 6.1 (5.6‐8.1) | .438 | 7.4 (6.7‐1.5) | 6.1 (5.0‐7.8) | .568 |
| Anthropometry/body composition | ||||||
| Weight (kg) | 95.6 (89.3‐108.2) | 94.0 (85.9‐107.8) | .006 | 101.7 (91.0‐116.5) | 96.8 (87.1‐114.0) | .000 |
| BMI (kg/m2) | 33.2 (29.6‐37.0) | 32.1 (29.3‐36.7) | .069 | 34.8 (33.0‐38.7) | 33.1 (31.2‐39.0) | .000 |
| Fat‐free mass (kg) | 63.3 (48.8‐65.9) | 6.8 (49.5‐65.8) | .052 | 61.5 (48.8‐72.2) | 59.2 (48.4‐67.4) | .296 |
| Fat mass (kg) | 38.7 (28.8‐48.2) | 37.8 (26.7‐44.9) | .108 | 41.0 (34.0‐51.2) | 36.5 (3.1‐5.0) | .107 |
| Total body water (L) | 46.4 (36.7‐49.1) | 44.3 (37.4‐48.5) | .016 | 46.3 (38.3‐53.7) | 44.3 (36.5‐49.8) | .300 |
| Visceral fat (L) | 4.1 (3.2‐6.9) | 4.0 (3.3‐5.4) | .305 | 5.2 (3.8‐7.4) | 4.5 (3.9‐5.5) | .211 |
| WC (cm) | 111 (106‐121) | 112 (104‐117) | .427 | 120 (112‐129) | 118 (114‐120) | .160 |
| Phase angle | 5.3 (5.0‐5.6) | 5.2 (4.9‐5.5) | .093 | 4.8 (4.5‐5.3) | 5.0 (4.8‐5.7) | .414 |
| Biochemistry | ||||||
| Liver function tests | ||||||
| AST (U/L) | 25 (18‐35) | 25 (17‐32) | .045 | 21 (19‐28) | 21 (20‐25) | .508 |
| ALT (U/L) | 32 (25‐52) | 29 (23‐43) | .052 | 26 (21‐30) | 25 (18‐35) | .029 |
| γ‐GT (U/L) | 48 (28‐71) | 34 (24‐49) | .385 | 33 (24‐51) | 32 (25‐39) | .082 |
| AP (U/L) | 80 (66‐87) | 70 (58.5‐87.5) | .264 | 75 (61‐106) | 74 (65‐121) | .714 |
| Glucose‐related parameters | ||||||
| HbA1c (%) | 8.4 (7.2‐9.2) | 7.6 (7.1‐8.0) | .000 | 7.6 (7.2‐8.8) | 7.2 (6.7‐7.6) | .006 |
| FPG (mg/dL) | 160 (139‐221) | 143 (129‐165) | .001 | 186 (146‐198) | 129 (117‐137) | .006 |
| Insulin (mIU/mL) | 11.6 (10.7‐16.1) | 1.9 (4.6‐15.4) | .188 | 17.1 (1.9‐25.7) | 14.8 (9.7‐31.0) | .720 |
| C‐Peptide (ng/mL) | 2.6 (1.9‐3.1) | 2.3 (1.5‐2.8) | .075 | 2.8 (1.8‐3.3) | 2.2 (1.4‐3.0) | .470 |
| HOMA‐IR score (FPGXIns/405) | 4.9 (3.8‐8.9) | 4.0 (1.5‐4.8) | .026 | 8.0 (5.0‐12.3) | 4.7 (2.7‐1.4) | .277 |
| Lipid status | ||||||
| TG (mg/dL) | 165 (123‐259) | 163 (121‐197) | .104 | 153 (92‐255) | 121 (93‐179) | .580 |
| TC (mg/dL) | 182 (166‐205) | 165 (123‐259) | .463 | 171 (141‐192) | 163 (127‐177) | .101 |
| LDL‐C (mg/dL) | 105 (86‐122) | 112 (87‐147) | .105 | 102 (87‐122) | 98 (63‐114) | .055 |
| HDL‐C (mg/dL) | 46 (38‐51) | 47 (42‐61) | .040 | 42 (37‐47) | 43 (42‐48) | .093 |
Significant P‐values are highlighted in bold.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment measuring insulin resistance; LDL, low‐density lipoprotein; LSM, liver stiffness measurement; TC, total cholesterol; TG, triglyceride; WC, waist circumference; γ‐GT, gamma‐glutamyl transpeptidase.